vs
Side-by-side financial comparison of Arteris, Inc. (AIP) and CHAMPIONS ONCOLOGY, INC. (CSBR). Click either name above to swap in a different company.
Arteris, Inc. is the larger business by last-quarter revenue ($20.1M vs $15.0M, roughly 1.3× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -42.2%, a 44.0% gap on every dollar of revenue. On growth, Arteris, Inc. posted the faster year-over-year revenue change (30.0% vs 11.5%). Arteris, Inc. produced more free cash flow last quarter ($3.0M vs $-2.0M). Over the past eight quarters, Arteris, Inc.'s revenue compounded faster (24.7% CAGR vs 11.8%).
Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
AIP vs CSBR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.1M | $15.0M |
| Net Profit | $-8.5M | $268.0K |
| Gross Margin | 90.8% | 51.7% |
| Operating Margin | -42.0% | 1.2% |
| Net Margin | -42.2% | 1.8% |
| Revenue YoY | 30.0% | 11.5% |
| Net Profit YoY | -3.7% | -63.2% |
| EPS (diluted) | $-0.19 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.1M | $15.0M | ||
| Q3 25 | $17.4M | $14.0M | ||
| Q2 25 | $16.5M | $12.4M | ||
| Q1 25 | $16.5M | $17.0M | ||
| Q4 24 | $15.5M | $13.5M | ||
| Q3 24 | $14.7M | $14.1M | ||
| Q2 24 | $14.6M | $14.0M | ||
| Q1 24 | $12.9M | $12.0M |
| Q4 25 | $-8.5M | $268.0K | ||
| Q3 25 | $-9.0M | $-436.0K | ||
| Q2 25 | $-9.1M | $-1.8M | ||
| Q1 25 | $-8.1M | $4.5M | ||
| Q4 24 | $-8.2M | $728.0K | ||
| Q3 24 | $-7.7M | $1.3M | ||
| Q2 24 | $-8.3M | $-109.0K | ||
| Q1 24 | $-9.4M | $-2.5M |
| Q4 25 | 90.8% | 51.7% | ||
| Q3 25 | 89.9% | 42.9% | ||
| Q2 25 | 89.4% | 41.1% | ||
| Q1 25 | 90.8% | 61.2% | ||
| Q4 24 | 89.8% | 44.9% | ||
| Q3 24 | 90.1% | 49.7% | ||
| Q2 24 | 90.0% | 48.2% | ||
| Q1 24 | 88.7% | 34.7% |
| Q4 25 | -42.0% | 1.2% | ||
| Q3 25 | -50.1% | -3.8% | ||
| Q2 25 | -50.0% | -16.2% | ||
| Q1 25 | -46.6% | 26.4% | ||
| Q4 24 | -45.9% | 5.4% | ||
| Q3 24 | -53.8% | 9.5% | ||
| Q2 24 | -51.1% | -1.9% | ||
| Q1 24 | -70.5% | -21.4% |
| Q4 25 | -42.2% | 1.8% | ||
| Q3 25 | -51.6% | -3.1% | ||
| Q2 25 | -55.3% | -14.9% | ||
| Q1 25 | -49.1% | 26.4% | ||
| Q4 24 | -53.0% | 5.4% | ||
| Q3 24 | -52.2% | 9.3% | ||
| Q2 24 | -57.2% | -0.8% | ||
| Q1 24 | -72.6% | -21.1% |
| Q4 25 | $-0.19 | $0.02 | ||
| Q3 25 | $-0.21 | $-0.03 | ||
| Q2 25 | $-0.22 | $-0.12 | ||
| Q1 25 | $-0.20 | $0.31 | ||
| Q4 24 | $-0.19 | $0.05 | ||
| Q3 24 | $-0.20 | $0.09 | ||
| Q2 24 | $-0.22 | $-0.01 | ||
| Q1 24 | $-0.25 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.9M | $8.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-14.6M | $4.2M |
| Total Assets | $115.0M | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.9M | $8.5M | ||
| Q3 25 | $39.0M | $10.3M | ||
| Q2 25 | $38.0M | $9.8M | ||
| Q1 25 | $42.3M | $3.2M | ||
| Q4 24 | $43.8M | $2.8M | ||
| Q3 24 | $48.7M | $2.9M | ||
| Q2 24 | $45.8M | $2.6M | ||
| Q1 24 | $44.8M | $4.5M |
| Q4 25 | $-14.6M | $4.2M | ||
| Q3 25 | $-11.4M | $3.5M | ||
| Q2 25 | $-7.5M | $3.8M | ||
| Q1 25 | $-4.8M | $5.5M | ||
| Q4 24 | $-1.2M | $681.0K | ||
| Q3 24 | $2.2M | $-332.0K | ||
| Q2 24 | $5.3M | $-1.9M | ||
| Q1 24 | $9.5M | $-2.1M |
| Q4 25 | $115.0M | $30.2M | ||
| Q3 25 | $107.7M | $30.5M | ||
| Q2 25 | $106.9M | $32.3M | ||
| Q1 25 | $98.3M | $30.6M | ||
| Q4 24 | $106.1M | $25.2M | ||
| Q3 24 | $97.7M | $24.9M | ||
| Q2 24 | $96.4M | $26.1M | ||
| Q1 24 | $101.4M | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $-1.7M |
| Free Cash FlowOCF − Capex | $3.0M | $-2.0M |
| FCF MarginFCF / Revenue | 15.1% | -13.1% |
| Capex IntensityCapex / Revenue | 0.7% | 1.6% |
| Cash ConversionOCF / Net Profit | — | -6.47× |
| TTM Free Cash FlowTrailing 4 quarters | $5.3M | $5.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $-1.7M | ||
| Q3 25 | $3.2M | $600.0K | ||
| Q2 25 | $-2.5M | $6.9M | ||
| Q1 25 | $2.9M | $490.0K | ||
| Q4 24 | $-2.6M | $-283.0K | ||
| Q3 24 | $1.1M | $311.0K | ||
| Q2 24 | $311.0K | $-1.8M | ||
| Q1 24 | $477.0K | $-919.0K |
| Q4 25 | $3.0M | $-2.0M | ||
| Q3 25 | $2.5M | $554.0K | ||
| Q2 25 | $-2.8M | $6.6M | ||
| Q1 25 | $2.7M | $448.0K | ||
| Q4 24 | $-2.7M | $-377.0K | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $264.0K | $-1.8M | ||
| Q1 24 | $281.0K | $-1.0M |
| Q4 25 | 15.1% | -13.1% | ||
| Q3 25 | 14.2% | 4.0% | ||
| Q2 25 | -17.2% | 53.5% | ||
| Q1 25 | 16.2% | 2.6% | ||
| Q4 24 | -17.3% | -2.8% | ||
| Q3 24 | 7.4% | — | ||
| Q2 24 | 1.8% | -13.0% | ||
| Q1 24 | 2.2% | -8.4% |
| Q4 25 | 0.7% | 1.6% | ||
| Q3 25 | 4.1% | 0.3% | ||
| Q2 25 | 2.2% | 2.0% | ||
| Q1 25 | 1.1% | 0.2% | ||
| Q4 24 | 0.3% | 0.7% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.3% | 0.0% | ||
| Q1 24 | 1.5% | 0.8% |
| Q4 25 | — | -6.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | -0.39× | ||
| Q3 24 | — | 0.24× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIP
| License And Maintenance | $17.5M | 87% |
| Variable Royalties And Other | $2.6M | 13% |
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
